A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers
Paul Spearman(Cincinnati Children's Hospital Medical Center), Michelle Lally(Brown University), Yunda Huang(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Marnie Elizaga(Fred Hutch Cancer Center), Georgia D. Tomaras(National Institutes of Health), John Donnelly(United States Military Academy), Lawrence Corey(Fred Hutch Cancer Center), Alicia Sato, Susan W. Barnett, Sharon E. Frey(St. Louis VA Medical Center), M. Juliana McElrath(Fred Hutch Cancer Center), Stephen C. De Rosa(University of Washington), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), David C. Montefiori(Duke University), Paul Sato(Family Health International 360)
Cited by 79
Related Papers
Integrated analysis of multimodal single-cell data
|Cell|2021|16.2k
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus
|Cell|2020|4.5k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
|Science|1993|2.3k
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation
|Journal of Immunological Methods|2003|1.6k